TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06188728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner
Description: comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of life style modification (Diet, Behavior and physical activity)
Description: To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined effect of 10 gm Psyllium husk fiber and lifestyle modification
Description: To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No intervention
Study: NCT04451694

Intervention type: OTHER
Intervention: nutritional intervention
Description: nutritional evaluation and intervention and orientation towards adapted care establishment
Study: NCT00922038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash reward
Description: Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash reward
Description: Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
Study: NCT02559921

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG（20 IU/kg）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhRIG（20 IU/kg） and vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhRIG（40 IU/kg） and vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRIG（20 IU/kg） and vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo and vaccine
Study: NCT01908374

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich fish oil versus Phospholipid-rich fish oil
Description: This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil versus Phospholipid-rich fish oil
Description: This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
Study: NCT04059978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: 1600mg cannabidiol, single oral dose (8 ml oily solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o, single oral dose (8 ml oily solution)
Study: NCT03175250

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action Plan
Description: Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Practice
Description: Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
Study: NCT00493844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise testing
Description: Exercise testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation + NTproBNP
Description: Clinical evaluation + NTproBNP levels
Study: NCT01729676

Intervention type: DRUG
Intervention: Degarelix or GnRH agonist
Description: Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
Study: NCT01976585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuFlt3L/CDX-301
Description: rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
Study: NCT05935813

Intervention type: OTHER
Intervention: Study characteristics of adolescents affected by dental caries
Description: Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).

Intervention type: OTHER
Intervention: Study characteristics of adolescents affected by dental caries
Description: Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).

Intervention type: OTHER
Intervention: Study characteristics of adolescents affected by dental caries
Description: Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).

Intervention type: OTHER
Intervention: Study characteristics of adolescents affected by dental caries
Description: Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).

Intervention type: OTHER
Intervention: Study characteristics of adolescents affected by dental caries
Description: Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).

Intervention type: OTHER
Intervention: Study characteristics of adolescents affected by dental caries
Description: Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).

Intervention type: OTHER
Intervention: Study characteristics of adolescents affected by dental caries
Description: Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).
Study: NCT03540641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture MagPro R30
Description: the subjects will receive 1500 or 5000 pulses at 5Hz

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagVenture MagPro R30
Description: the subjects will receive 1500 or 5000 pulses at 5Hz

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture MagPro R30
Description: the subjects will receive 1500 or 5000 pulses at 5Hz

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagVenture MagPro R30
Description: the subjects will receive 1500 or 5000 pulses at 5Hz
Study: NCT04580836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT01144741

Intervention type: OTHER
Intervention: Functional Enquiry (or Review of Systems) Form
Description: Completed during the interview; it is a checklist of medical problems.

Intervention type: OTHER
Intervention: Functional Enquiry (or Review of Systems) Form
Description: Completed during the interview; it is a checklist of medical problems.

Intervention type: OTHER
Intervention: Functional Enquiry (or Review of Systems) Form
Description: Completed during the interview; it is a checklist of medical problems.

Intervention type: OTHER
Intervention: Functional Enquiry (or Review of Systems) Form
Description: Completed during the interview; it is a checklist of medical problems.

Intervention type: OTHER
Intervention: Functional Enquiry (or Review of Systems) Form
Description: Completed during the interview; it is a checklist of medical problems.

Intervention type: OTHER
Intervention: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire
Description: The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.

Intervention type: OTHER
Intervention: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire
Description: The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.

Intervention type: OTHER
Intervention: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire
Description: The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
Study: NCT04059978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.1 µg/kg/min i.v. for 30 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.1 µg/kg/min i.v. for 30 min
Study: NCT01144741

Intervention type: OTHER
Intervention: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire
Description: The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
Study: NCT01919723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor loading dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor loading dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: i.v. infusion
Study: NCT03641807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
Study: NCT02645565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: azathioprine will be given at 2 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: azathioprine will be given at 2 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
Study: NCT00082368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tariquidar
Description: 3 days after initial PET patients will receive tariquidar and repeat imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-94m Sestamibi
Description: Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
Study: NCT00107900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Study: NCT01919723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: i.v. infusion
Study: NCT02147197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: UPA tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: UPA tablet
Study: NCT03119922

Intervention type: OTHER
Intervention: No intervention
Study: NCT01478386

Intervention type: OTHER
Group type: OTHER
Intervention: Orthovisc
Description: Subjects will receive a series of three Orthovisc injections into their affected knee
Study: NCT02147197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.
Study: NCT02764515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kunxian Capsule
Description: Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
Study: NCT03605225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile cellphone application test
Description: Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
Study: NCT02764515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
Study: NCT00801632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplantation
Description: Surgical transplantation of donor kidney
Study: NCT01478386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DonJoy HA lite knee brace
Description: Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthovisc injections and DonJoy HA lite knee brace
Description: Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
Study: NCT03839823

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel / Capecitabine
Description: Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine / Vinorelbine
Description: Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day \[oral\] or (25 to 30 mg/m2 \[IV infusion\]

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel / Gemcitabine
Description: Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
Study: NCT01087359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
Study: NCT00206986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 0.15 mg of clonidine will be administered to 20 healthy male volunteers
Study: NCT01078285

Intervention type: BEHAVIORAL
Intervention: No Patient Counseling
Description: Patients do not receive any adherence counseling, or other patient support services
Study: NCT02147197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.
Study: NCT00801632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg infusion on days -5, -4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 infusion on days -7, -2, 5, and 12
Study: NCT01700959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets to match the melatonin will be comprised of inert substances.
Study: NCT00801632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thymic irradiation
Description: 700 cGy of thymic irradiation administered in a single dose on day -1
Study: NCT03146559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG and TENS
Description: Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS only
Description: Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).